Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Smoking, Headaches And Allergies: Rx Pipeline Drugs May Impact OTCs

This article was originally published in The Tan Sheet

Executive Summary

Pfizer and Schering-Plough are developing a number of new prescription drugs and line extensions that could make inroads into large OTC categories
Advertisement

Related Content

Claritin Growth Plateaus As Schering Moves Ahead With Consent Decree
Claritin Growth Plateaus As Schering Moves Ahead With Consent Decree
Pfizer Ad Says OTCs “Aren’t As Safe As You Might Think”
Pfizer Touts Relpax Efficacy Versus Excedrin Migraine In Study

Topics

Advertisement
UsernamePublicRestriction

Register

PS097602

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel